Vice President, Controller
Immunic Therapeutics
Summary
We are seeking a VP Corporate Controller to lead our accounting function as Immunic transitions from clinical-stage development to commercial operations.
Job description
Summary
We are seeking a VP Corporate Controller to lead our accounting function as Immunic transitions from clinical-stage development to commercial operations.
Reporting to the Executive VP of Finance, you will lead the accounting team and own the close, SEC reporting, internal controls and gross-to-net revenue accounting, partnering closely with Commercial, Market Access and Trade/Distribution.
You will join us as we build the finance infrastructure, controls, systems and team needed for the anticipated U.S. launch of our first product. The ideal candidate combines deep commercial-stage gross-to-net expertise with a hands-on, builder mindset and must be based on the east coast with direct biotech experience through Phase III.
Responsibilities
- Design, implement and own gross-to-net (GTN) revenue accounting for our first commercial product, including reserves for chargebacks, rebates (commercial, Medicaid, Medicare Part D, 340B), distribution and data fees, co-pay assistance, returns and prompt-pay discounts.
- Develop audit-ready GTN estimation methodologies, roll-forwards and true-up processes, applying ASC 606 variable consideration principles.
- Partner with Market Access, Trade and Government Pricing to align contract terms, channel data and government pricing calculations (AMP, Best Price, ASP, Non-FAMP) with accounting.
- Establish inventory accounting and costing (ASC 330), including pre-launch inventory capitalization, standard costing, CMO/3PL reconciliations and excess/obsolescence reserves.
- Lead the monthly, quarterly and annual close, including clinical trial accruals, stock-based compensation, leases and other technical areas.
- Prepare and review Forms 10-Q and 10-K, footnotes and supporting schedules in partnership with the CFO and SEC reporting resources.
- Design and maintain a SOX-compliant internal control environment, scaling controls for new commercial processes (order-to-cash, GTN, inventory, procure-to-pay).
- Serve as primary liaison with external auditors for quarterly reviews and the annual audit, and prepare technical accounting memos (with external consultants as needed) for new transactions and commercial arrangements.
- Support the selection and implementation of a commercial-ready ERP and related systems, including GTN/revenue management and 3PL integrations.
- Build, lead and develop a high-performing accounting team, manage outsourced accounting partners, and partner with FP&A on budgeting, forecasting and launch-related financial analysis.
Qualifications & Education
- Bachelor's degree in Accounting; CPA (active or inactive) required.
- 10+ years of progressive accounting experience, including Big 4 public accounting and public-company industry experience.
- Direct, hands-on gross-to-net accounting experience at a commercial-stage pharmaceutical or biotechnology company, including establishing or managing GTN reserves and accruals.
- Strong knowledge of U.S. GAAP (particularly ASC 606 and ASC 330), SEC reporting requirements and SOX 404 compliance, including designing internal controls.
- Demonstrated ability to lead a close process and to manage and develop staff.
- Excellent communication skills and the ability to partner cross-functionally with commercial and operational teams.
- A builder mindset: hands-on, detail-oriented and strategic, with high integrity, sound judgment and strong ownership in a fast-paced, evolving environment.
- Experience with Oracle NetSuite as an end user or administrator, ideally including a key role in a NetSuite implementation at a life sciences company preparing for commercialization, preferred.
- Experience with Workiva for SEC reporting (10-Q/10-K, XBRL tagging) preferred.
- Experience with a product launch, building commercial accounting processes from the ground up, preferred.
- Familiarity with government pricing, the Medicaid Drug Rebate Program, 340B and specialty distribution models preferred.
- Experience with GTN/contract management systems (e.g. Model N, IntegriChain, Revitas) preferred.
Requirements
- Bachelor's degree in Accounting
- CPA (active or inactive) required
- 10+ years of progressive accounting experience
- Big 4 public accounting experience
- Public-company industry experience
- Direct, hands-on gross-to-net accounting experience at a commercial-stage pharmaceutical or biotechnology company
- Establishing or managing GTN reserves and accruals
- Strong knowledge of U.S. GAAP (ASC 606 and ASC 330)
- SEC reporting requirements
- SOX 404 compliance, including designing internal controls
- Demonstrated ability to lead a close process
- Ability to manage and develop staff
- Excellent communication skills
- Ability to partner cross-functionally with commercial and operational teams
- Builder mindset: hands-on, detail-oriented and strategic
- High integrity, sound judgment and strong ownership
- Must be based on the east coast
- Direct biotech experience through Phase III
- Oracle NetSuite experience preferred
- Workiva for SEC reporting preferred
- Product launch experience preferred
- Government pricing, Medicaid Drug Rebate Program, 340B and specialty distribution familiarity preferred
- GTN/contract management systems (Model N, IntegriChain, Revitas) experience preferred
Benefits
- Equity
- Bonus
Company overview
Immunic Therapeutics (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for chronic inflammatory and autoimmune diseases, with a primary focus on neurologic conditions such as multiple sclerosis (MS). Headquartered in New York City with additional operations in Gräfelfing, Germany, the company is dedicated to advancing a clinical pipeline of orally administered, small molecule therapeutics. Its lead program, vidofludimus calcium (IMU-838), is a first-in-class oral therapy that combines neuroprotective effects through nuclear receptor-related 1 (Nurr1) activation with anti-inflammatory and anti-viral properties via selective dihydroorotate dehydrogenase (DHODH) inhibition. Vidofludimus calcium is currently in Phase 3 clinical trials (ENSURE program) for relapsing multiple sclerosis, with top-line data expected by the end of 2026, and has demonstrated promising therapeutic activity in Phase 2 trials for both relapsing-remitting and progressive MS. The company's pipeline also includes earlier-stage programs, such as IMU-856 targeting gastrointestinal diseases and IMU-381 for gastrointestinal applications. Founded in 2016, Immunic employs approximately 51-200 people and is transitioning toward becoming a fully integrated commercial-stage biotechnology company.